Sign In
Buy BAYRY
$13.89
-0.110 (-0.786%)
At Close: Jul 31, 2026
Bayer reports positive results for blood thinner after 2023 setback
11:48am, Sunday, 23'rd Nov 2025
German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
BERLIN--(BUSINESS WIRE)--Bayer today announced positive topline results from the global Phase III study OCEANIC-STROKE, with its investigational, once daily, oral FXIa inhibitor asundexian. The study
FDA Signs Off On Bayer's New Lung Cancer Drug — Early Results Look Promising
12:53pm, Thursday, 20'th Nov 2025
The Food and Drug Administration (FDA) on Wednesday granted accelerated approval to Bayer AG‘s (OTC: BAYRY) Hyrnuo (sevabertinib) for adults with a specific type of advanced lung cancer.
Bayer Just Cracked the Lung Cancer Market--Here's Why Investors Are Paying Attention
06:42am, Thursday, 20'th Nov 2025
Bayer AG (BAYRY) just picked up a shot of momentum from the US Food and Drug Administration, which granted accelerated approval for Hyrnuo, its new treatment fo
US FDA approves Bayer's lung cancer drug
02:53pm, Wednesday, 19'th Nov 2025
The U.S. Food and Drug Administration on Wednesday approved Bayer's drug for patients with a type of lung cancer.
BAYRY Obtains Approval for Hormone Free VMS Treatment Lynkuet in the EU
09:56am, Wednesday, 19'th Nov 2025
Bayer BAYRY obtained European Commission approval for elinzanetant for the treatment of moderate to severe vasomotor symptoms (VMS, also known as hot flashes) associated with menopause or caused by ad
Why Bayer Aktiengesellschaft (BAYRY) is a Top Value Stock for the Long-Term
10:41am, Friday, 14'th Nov 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Bayer Aktiengesellschaft (BAYRY) Q3 2025 Earnings Call Transcript
06:01pm, Wednesday, 12'th Nov 2025
Bayer Aktiengesellschaft (OTCPK:BAYRY) Q3 2025 Earnings Call November 12, 2025 8:00 AM EST Company Participants Jost Reinhard - Senior VP & Head of Investor Relations William Anderson - Chairman of th
Agricultural Conglomerate Bayer Confident In Long-Term Outlook Despite Litigation Risks
01:34pm, Wednesday, 12'th Nov 2025
On Wednesday, Bayer AG (OTC:BAYRY) reported adjusted earnings of 17 cents per ADS (57 cents in euros), up from 7 cents a year ago (24 cents euros).
Bayer Q3 Earnings Beat Estimates on Crop Science Business Gains
01:31pm, Wednesday, 12'th Nov 2025
Bayer's Q3 earnings surged on Crop Science strength, offsetting pricing and currency headwinds across divisions.
Kahn Brothers' Strategic Moves: GSK PLC Sees a -3.08% Impact
12:00pm, Wednesday, 12'th Nov 2025
Exploring Kahn Brothers (Trades, Portfolio)' Recent 13F Filing and Investment Strategies Kahn Brothers (Trades, Portfolio) recently submitted their 13F filing
Bayer share price forecast after earnings: is it a good buy today?
03:22am, Wednesday, 12'th Nov 2025
The Bayer share price jumped by over 3% after the company published encouraging financial results. BAYN jumped to a high of €27.43 a, up from this month's low of €25.74.
Bayer Posts Net Loss on Litigation Hit
02:39am, Wednesday, 12'th Nov 2025
Bayer's net loss narrowed in the third quarter but additional litigation provisions weighed on its crop-science business.
Bayer's third-quarter adjusted profit beats market view
01:46am, Wednesday, 12'th Nov 2025
Bayer said on Wednesday that third-quarter adjusted operating income gained 20.8%, citing gains at the Crop Science division and reconciliation effects in accounting.
Bayer Launches “Science Delivers” Campaign Celebrating the Transformative Power of Science
07:01am, Monday, 10'th Nov 2025
ST. LOUIS--(BUSINESS WIRE)--Today, on World Science Day, Bayer is proud to launch its “Science Delivers” campaign, a nationwide initiative celebrating how science delivers answers, hope, and progr
